Shattuck Labs Announces Drug Discovery Collaboration With Ono Pharmaceutical, For Bifunctional Fusion Proteins Targeting Certain Autoimmune And Inflammatory Disease Pathways, Shattuck To Receive Upfront And Be Eligible For Milestone Payments Of Upto $227M
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs has entered into a drug discovery collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. Shattuck will receive an upfront payment and is eligible for milestone payments totaling up to $227 million.
February 13, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shattuck Labs enters a significant collaboration with Ono Pharmaceutical, receiving an upfront payment and eligibility for up to $227M in milestones for autoimmune and inflammatory disease treatments.
The collaboration with Ono Pharmaceutical represents a significant development for Shattuck Labs, potentially bringing substantial financial inflows through upfront and milestone payments. This partnership not only validates Shattuck's technology and approach but also provides a financial runway to advance its pipeline, likely leading to positive investor sentiment and a potential increase in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100